A Sachet Is a Regulatory Instrument: Where Monodose Grows and Where Europe Bans It

One word, two businesses

Two sentences, both true inside the same three-year window, describe the same packaging format. In the European Union, single-use plastic packaging for individual portions — condiment and sauce sachets, creamer, sugar — and accommodation miniature toiletry packaging must leave the market from 1 January 2030. In ophthalmology and ear, nose and throat medicine, the sterile single dose has stopped being a novelty format and become the default. “Monodose” is the word for both, and any figure that adds them together is measuring a category that has already stopped behaving as one.

The split is not about size. A three-millilitre eye-drop vial and a five-gram ketchup sachet contain the same trivial amount of product in the same trivial amount of material. What separates them is why the dose exists. In one case the single dose substitutes for a preservative a clinician does not want in a patient’s eye. In the other it substitutes for a bottle a customer could have carried.

What Europe bans, and on what date

Regulation (EU) 2025/40 on packaging and packaging waste entered into force on 11 February 2025 and applies from 12 August 2026. Its restriction list takes effect on 1 January 2030 and removes single-use plastic packaging for five applications: unprocessed fresh fruit and vegetables; food and beverages filled and consumed in cafés and restaurants; individual portions such as condiments, sauces, creamer and sugar; accommodation miniature packaging for toiletry products; and very lightweight plastic carrier bags below 15 microns.

Two of those five are monodose packs in everything but name — the condiment sachet and the hotel miniature. The European Commission’s own summary of the law names the mechanism without ambiguity: restrictions on single-use plastics “such as for individual portions or sachets of condiments and sauces”.

The ban is only the loudest instrument. The same regulation sets packaging-reduction targets of 5% by 2030, 10% by 2035 and 15% by 2040 against a 2018 baseline; requires all packaging placed on the EU market to be recyclable in an economically viable way by 2030; caps empty space at 50% for grouped, transport and e-commerce packaging; and closes the composite-packaging escape route by stating that single-use packaging partly made of plastics cannot sidestep the Single-Use Plastics Directive by staying under a mass threshold.

Every one of those instruments presses on the same weakness of the sachet. It delivers a very small quantity of product through a very large amount of surface, and most of that surface is a multi-material laminate.

What Europe does not ban: the dose a clinician requires

The single dose that is growing is the one where the pack does clinical work rather than convenience work. Preservative-free eye drops are the clearest and largest case. A multi-dose bottle needs a preservative to stay sterile after the first opening, and that preservative is the component most often implicated in the irritation chronic patients report. A unit dose removes the preservative and the sensitisation pathway with it. LF of America, a contract packager, identifies ophthalmic products as the largest pharmaceutical application for unit-dose packaging for precisely this reason.

The capacity behind the format is industrial rather than boutique. Unither Pharmaceuticals, which describes itself as the world leader in sterile single doses, reports more than 5 billion doses a year of capacity across 14 blow-fill-seal lines and nine sites. Its own account of the format’s history is the sentence that matters for anyone sizing it: twenty years ago single-dose packaging was still just a new dosage form, and it has now become the standard in therapeutic areas such as ophthalmology and ENT, driven by changes in medical practice, treatment and patient need.

The monodose did not win in medicine because consumers like sachets. It won because a single sterile dose answers three clinical problems at once — no preservative, no over-dosing, no contamination pathway after opening — and because the process that makes it is cheaper to validate than the alternative it replaces.

Why blow-fill-seal moves the value out of packaging

Blow-fill-seal forms the container, fills it and seals it inside one machine, in a single aseptic sequence, with no direct human intervention. Read that as a supply-chain statement rather than a process description: the container does not exist until the moment it is filled, so sterility becomes a property of the machine instead of a property of the room, the operator and the handling.

The commercial consequence is that a monodose pack is not, in any meaningful sense, bought from a packaging company. It is bought from whoever owns a validated line — a machine builder or a contract filler — and what is being qualified is the aseptic process: media fills, container-closure integrity, change control, the whole documentation stack. Unither states that its lines operate in compliance with EU, FDA, ANVISA and NMPA GMP. That is a moat built out of paperwork, and it is not one a film converter crosses by buying a different laminate.

This is the inversion most packaging analysis misses. In flexible formats, value sits with the converter who owns the structure. In aseptic monodose, value sits with the line owner, and the pack is a by-product of a manufacturing qualification that takes years and cannot be bought second-hand.

Cosmetics uses the same word for two opposite products

The ampoule — the glass or plastic single-dose serum — is sold as a premium format. It carries a price per millilitre above the bottle it replaces, it supports a preservation-free claim, and it turns an ingredient claim into a visible ritual. That is a pack with pricing power, and it is why single-dose serums survived a decade in which unit-dose packaging was supposed to commoditise.

The sample sachet is its opposite in every commercial respect. It is a marketing cost distributed free at the point of trial, its cost per unit of product delivered is the worst in the format’s repertoire, and its disposal falls on the consumer with no revenue attached to it. It is also the format a per-unit packaging fee hits hardest, and the one the 2030 accommodation-miniature restriction reaches directly at the hotel end of the distribution chain.

Both sit under one keyword in most market reports. In a procurement decision they have different buyers — brand marketing versus formulation — different cost lines, and, from 2030, different legal status inside the European Union.

The barrier problem, and the winner nobody calls sustainable

A sachet has to do with a few microns of film what a bottle does with a millimetre of wall: hold a fragrance, hold an oil, hold an acid, and keep oxygen out for two years. The conventional answer is a laminate — PET, aluminium foil, polyethylene — and a laminate is the structure that design-for-recycling rules like least. RecyClass’s design guidance for flexible plastic packaging is specific about what is tolerable: coextruded structures are more favourable than laminated ones because they can follow a mono-material approach; full-PE or full-PP multilayer is the recommended route, with limited cross-contamination at roughly 5% PP in a PE stream and 10% PE in a PP stream; EVOH barrier is permissible at or below 5% by weight with tie layers, while polyamide, metallisation and PVOH are not cleared. The same guidance warns that inks should be avoided on transparent films because they contaminate the recyclate.

Now set that against a blow-fill-seal ampoule. It is one polymer — polyethylene or polypropylene — formed into a rigid container, with no adhesive, no foil, no printed film and no label. Measured against every criterion in that guidance, the aseptic plastic ampoule is a cleaner recyclate stream than the cosmetic sachet carrying the same product, and it is the one format in this comparison that nobody markets as sustainable packaging.

That is the inversion worth carrying into an investment case. The clinical monodose is both the faster-growing and the more recyclable of the two. The convenience monodose is both the one being legislated away and the one that is hardest to make mono-material.

Why there is no defensible size for “monodose”

A single market figure for this category is only useful if it separates the two businesses described above, and the standard construction does the opposite: condiment sachets, hotel toiletries, pharmaceutical unit doses, cosmetic samples and foodservice portions are added into one number. That is exactly the aggregation the 2030 restriction list breaks, because four of those five applications move in different directions inside the same forecast window.

Pheonix Research publishes no standalone monodose market size, and this article does not substitute one. The defensible quantities sit one level down, at the application and at the line: five billion doses a year of sterile single-dose capacity at a single contract filler is a fact that can be checked, and “the monodose market” is not.

What to watch

• 1 January 2030. The condiment sachet and the hotel miniature leave the EU market. A converter with those applications in its book has roughly one product cycle to replace them, and the replacement is a refillable dispenser or a mono-material alternative — not a thinner laminate.
• 12 August 2026. The regulation applies. Reduction targets, empty-space limits and design-for-recycling criteria start entering retailer and brand specifications long before the ban list bites.
• Recyclability by 2030. For every cosmetic sachet the question is whether the structure can convert to coextruded PE or PP with EVOH at or below 5%. That is a film redesign plus a seal-strength requalification plus a stability re-run, not a material substitution.
• Blow-fill-seal capacity. Five billion doses at one filler is a number that becomes a bottleneck the moment a large ophthalmic or biologic molecule switches format.
• Preservative-free conversion. Every ophthalmic molecule that moves from a preserved bottle to a unit dose adds volume to the clinical side of the split — and that conversion is a regulatory filing before it is a packaging change.
• The ampoule’s premium. Single-dose serums hold a price per millilitre above bottled equivalents. The test is whether that premium survives a recycling fee charged per unit rather than per gram.

The format is neither dying nor booming. It is separating, and the line runs along whether a regulator or a clinician is the reason the dose exists.